The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AGMB | N/A | N/A | N/A | N/A |
| S&P | +12.16% | +74.91% | +11.82% | N/A |
No news articles found for AgomAb Therapeutics.
| Q4 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$90.67K | 0.0% |
| Net Income | -$12,514.44K | 0.0% |
| EBITDA | -$12,919.78K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2024 | YOY Change | |
|---|---|---|
| Net Cash | $27.40M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.32M | 0.0% |
| Short Term Debt | $282.69K | 0.0% |
No data available for this period.
No data available for this period.
| Metric | Q4 2024 | YoY Change |
|---|---|---|
| Total Debt | $1.60M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
